Medicilon's Custom Peptide Synthesis Services

Medicilon offers custom synthetic peptides services with a wide range of scales, purity levels, modifications and labeling, which allow you to get the highest performance in your research. Through our manufacturing and development of peptides, we strive to provide a range of unique services that are not only high quality, but beneficial for our customers such as in the development of antibodies, substrates and probing protein-protein interactions. Our synthesis services are cost effective through our efficiency and knowledge, ensuring only the highest quality available.

custom peptide synthesis

❖ Medicilon’s Synthetic Chemistry Services

Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.

Chemical synthesized peptide drugs

Organic Chemistry Synthesis of Medicilon

Molecular Construction Method Allows Synthesis of Valuable Chiral Drugs

Peptides play a key role in many biochemical and immunological assays, including enzyme-substrate studies, blocking and competition assays, epitope mapping, T cell stimulation and many more. We bring you a custom peptide synthesis service that recognizes the importance of high quality reagents for these applications, delivered to you with a fast turnaround time and at excellent value.

We will help on design of peptides based on:
Blast database search for homology to the protein of interest and selection of the best region for peptide synthesis.
Protein antigenicity analysis.

Region hydrophilicity analysis.

Our peptide specialist will then choose a sequence with the best amino acid coupling efficiency.

Peptide Synthesis Services

○Micro to macro high throughput peptide arrays and peptide library synthesis

○Specialty peptide modifications

○Polyepitope peptides

○Ultra long peptides

○Peptide content determination to confirm identity and insure quality

○Full range of analyses including LC-MS (trap and/or quad), MALDI-MS, HPLC, AAA, NMR, CE, peptide sequencing

○Most peptides are shipped in five to seven working days accompanied by a Quality Assurance certificate

Your Quality Assurance

We guarantee the quality of each and every peptide produced. All purified peptides will be delivered with the MS/HPLC reports.

HPLC(High-performance liquid chromatography): All peptides synthesized will be purified using a new HPLC system with fraction collection capability. The purity of your peptide will be authenticated by a comprehensive HPLC data report.

HPLC-custom peptide manufacturing

MS: To confirm the identity of the synthesized peptide, we use a state-of-the-art Mass-Mass Spectrometer system to determine the exact molecular weight of the peptide. A detail Mass Spec report will be included with the peptide products.

Contact US

Email: marketing@medicilon.com
Tel: +86 021 58591500

Above is about peptide synthesis service, custom peptide synthesis price, peptide synthesis companies. Contact us to discuss your needs for Customized Protein Expression Services.

For more Services

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客